ClinicalTrials.gg
CompletedNCT03573310Updated Dec 18, 2025

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

A Phase 1 interventional study of JNJ-64619178 in Neoplasms, Solid Tumor, Adult and Non-Hodgkin Lymphoma, sponsored by Janssen Research & Development, LLC. Completed at 18 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.

Primary conditionLymphoma, Non-HodgkinRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Non-Hodgkin
Why
  1. The study's listed conditions name Lymphoma, Non-Hodgkin, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
114
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Lymphoma, Non-Hodgkin by Johnson & Johnson — 2 open to participants now, 7 under way, none of them phase 3. Lymphoma, Non-Hodgkin · Johnson & Johnson.

Enrollment
7th of 15
114 · median 85
Started
2018
the only one that year
Phase 1
13 of 17
2 open now
Registered
5th of 17
by date

Among the 17 studies in Lymphoma, Non-Hodgkin by Johnson & Johnson, this one is the 7th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2018, is one of 13 in phase 1, and was the 5th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

2 of the 17 studies in Lymphoma, Non-Hodgkin by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Lymphoma, Non-Hodgkin by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of the study is to identify the maximum tolerated dose (MTD) of JNJ-64619178 in participants with relapsed/refractory B cell non-Hodgkin lymphoma (NHL) or advanced solid tumors and also to identify the recommended Phase 2 dose(s) (RP2Ds) of JNJ-64619178 for NHL and advanced solid tumors (Part 1) and to confirm the tolerability of JNJ-64619178 in participants with lower risk myelodysplastic syndromes (MDS) (Part 2).

Read the detailed description

The study is designed to determine the maximum tolerated dose (MTD) of JNJ-64619178, and to select a dose(s) and regimen(s) that may be used in future clinical development. Study evaluations will include safety, pharmacokinetics, biomarkers and efficacy evaluations (Disease Assessments). Adverse events will be evaluated throughout the study. The study is divided into 4 periods: a screening phase, a pharmacokinetic run-in phase, a treatment phase, and a post treatment follow-up phase. An end-of-treatment visit will be completed less than or equal (\<=) 30 days (+7 days) after the last dose of study drug or prior to the start of a new anticancer therapy, whichever comes first.

03

Conditions studied

  • Neoplasms
  • Solid Tumor, Adult
  • Non-Hodgkin Lymphoma
  • Myelodysplastic Syndromes

Browse trials for

Keywords

  • Lower risk MDS
  • Low risk MDS
  • Lower-risk MDS
  • Low-risk MDS
  • Intermediate 1 risk MDS
  • Intermediate-1 risk MDS
04

In context

Lymphoma, Non-Hodgkin Reclassified

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

This study's enrollment of 114 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.

Browse Lymphoma, Non-Hodgkin studies →

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Compared within Lymphoma, Non-Hodgkin, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • B cell non-Hodgkin lymphoma (NHL) or solid tumors, or lower risk MDS
  • At least 1 measurable site of disease for B cell-NHL and solid tumors
  • (ECOG) performance status score of 0 or 1
  • Adequate organ function
  • Women of must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) at screening and prior to the first dose of study drug. Women must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of 90 days after receiving the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • History of, or known, central nervous system (CNS) involvement
  • Prior solid organ transplantation
  • Either of the following: a) Received an stem cell transplant less than or equal (\<=) 9 months before the first dose of study drug B) Prior treatment with allogenic stem cell transplant
  • History of (other than the disease under study) within 3 years before the first administration of study drug. Exceptions include squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years
  • Known allergies, , or intolerance to JNJ-64619178 or its
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Part 1: Dose escalation and RP2D Selection

    Participants with solid tumors or non-Hodgkin lymphoma (NHL) will receive JNJ-64619178 orally as per the assigned sequential cohorts and doses will be escalated based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and clinical activity. One or more recommended Phase 2 dose(s) (RP2Ds) may be determined for further exploration.

    Drug: JNJ-64619178

  • Experimental
    Part 2:Dose Confirmation and Expansion

    Participants with myelodysplastic syndromes (MDS) will receive JNJ-64619178 at a dose less than or equal to the RP2D selected in Part 1 for 24 weeks, or longer if there is evidence of clinical benefit. The dose level of JNJ-64619178 may be adjusted based on observed toxicities.

    Drug: JNJ-64619178

Interventions

  • DrugJNJ-64619178

    JNJ-64619178 capsules to be administered orally.

07

What researchers measure

Primary outcomes

  1. Part 1 and Part 2: Number of Participants with Dose-limiting Toxicities (DLTs)

    DLTs are defined as certain non-hematologic and hematologic toxicities of Grade 3 or higher.

    Time frame: Approximately 3 years

Secondary outcomes

  1. Part 1 and Part 2: Number of Participants with Adverse Events (AE)

    AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.

    Time frame: Approximately 3 years

  2. Part 1 and Part 2: Number of Participants with AE by Severity

    Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). Severity scale ranges from Grade 1 (Mild) to Grade 4 (Life-threatening). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

    Time frame: Approximately 3 years

  3. Part 1 and Part 2: Number of Participants with Abnormal Vital Signs

    Number of participants with abnormality in vital signs (temperature, pulse/heart rate, and blood pressure) will be reported.

    Time frame: Approximately 3 years

  4. Part 1 and Part 2: Number of Participants with Laboratory Abnormalities

    Number of participants with laboratory abnormalities (serum chemistry, hematology, and coagulation, and disease-related laboratory abnormalities) will be reported.

    Time frame: Approximately 3 years

  5. Part 1 and Part 2: Number of Participants with Electrocardiogram (ECG) Abnormalities

    Number of participants with electrocardiogram(ECG) abnormalities will be reported.

    Time frame: Approximately 3 years

  6. Part 1 and Part 2: Maximum Plasma Concentration (Cmax) of JNJ-64619178

    Cmax is the maximum observed plasma concentration.

    Time frame: Approximately 3 years

  7. Part 1 and Part 2: Area Under the Plasma Concentration Versus Time Curve From Time Zero to End of Dosing Interval (AUCtau)

    AUCtau is the measure of the plasma drug concentration from time zero to end of dosing interval.

    Time frame: Approximately 3 years

  8. Part 1 and Part 2: Minimum Plasma Concentration (Cmin)

    Cmin is the minimum observed plasma concentration.

    Time frame: Approximately 3 years

  9. Part 1 and Part 2: Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Approximately 3 years

  10. Part 1 and Part 2: Volume of Distribution at Steady-State Influenced by the Fraction Absorbed (Vss/F)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady state which is estimated by (D/AUC\[0-infinity\])\* (AUMC\[0-infinity\])/(AUC\[0-infinity\]) where D is the dose of study drug, AUMC(0-infinity) is the area under the first moment curve extrapolated to infinity and AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time. All these parameters will be assessed as influenced by the fraction absorbed.

    Time frame: Approximately 3 years

  11. Part 1 and Part 2: Apparent Total Systemic Clearance of Drug (CL/F) after Extravascular Administration

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Approximately 3 years

  12. Part 1 and Part 2: Accumulation Index (RA)

    Accumulation Index (RA) is calculated as AUC (0-24) value at steady state divided by AUC (0-24) value after first dose.

    Time frame: Approximately 3 years

  13. Part 1 and Part 2: Plasma Concentration of Symmetric Dimethyl-Arginine (SDMA)

    Plasma concentration of symmetric dimethyl-arginine (SDMA) will be evaluated.

    Time frame: Approximately 3 years

  14. Part 1: Percentage of Participants with B cell non-Hodgkin lymphoma (NHL) Showing Overall Response of Partial Response (PR) or Better

    Overall response rate (ORR) is defined as the percentage of participants who have a PR or better. Per Lugano classification, PR is defined as greater than or equal (\>=) 50 percent (%) decrease in size of target lesions.

    Time frame: Approximately 3 years

  15. Part 1: Percentage of Participants with Solid Tumors Showing Overall Response of PR or Better

    Overall response rate (ORR) is defined as the percentage of participants who have a PR or better. PR criteria in solid tumors (RECIST) is \>= 30 percent (%) decrease in the sum of the diameters of all index lesions compared with baseline in 2 observations at least 4 weeks apart, in absence of new lesions or unequivocal progression of non-index lesions.

    Time frame: Approximately 3 years

  16. Part 1: Duration of Response

    Duration of response (DOR) will be calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease (PD), as defined in the disease-specific response criteria, or death due to any cause, whichever occurs first. PD (per RECIST 1.1) defined as at least 20% increase in the sum of the longest diameters of index lesions or unequivocal progression of non-index lesions. Per Lugano classification, PD: target lesions larger; clear progression of non-target lesions; or new tumor lesions; new or recurrent bone marrow involvement; splenomegaly + 2 centimeter (cm) or +50%.

    Time frame: Approximately 3 years

  17. Part 1: Clinical Benefit Rate

    Clinical benefit rate is defined as percentage of participants who have a complete response (CR), PR and sustained stable disease of 12 weeks or more. Sustained stable disease of 12 weeks or more is defined as participants with stable disease assessment maintained for about 12 weeks or longer from baseline. Per Lugano classification CR is defined as no detectable disease by computed tomography (CT) or positron emission tomography (PET)/CT scan. Evaluation criteria as per RECIST 1.1 for CR is defined as disappearance of all lesions in 2 consecutive observations not less than 4 weeks apart.

    Time frame: Approximately 3 years

  18. Part 2: Red Blood Cell (RBC) Transfusion Independence (TI) Rate

    Percentage of participants with TI, defined as being without any transfusion during any consecutive 8 weeks (56 days) between the first dose of study drug and treatment discontinuation.

    Time frame: Approximately 3 years

  19. Part 2: Overall Improvement Rate

    Overall improvement rate is defined as the percentage of participants achieving complete remission (bone marrow: less than or equal to (\<=)5% myeloblasts with normal maturation of all cell lines; Peripheral blood: hemoglobin \>=11 gram per deciliter (g/dL); platelets \>=100\*109/liter(L); neutrophils \>=1.0\*109/L; blasts, 0%), partial remission (All complete remission criteria if abnormal before treatment except: Bone marrow blasts decreased by \>=50% over pretreatment but still \>5% Cellularity and morphology not relevant), or hematologic improvement (HI) (Erythroid response \[pretreatment, \<11 g/dL\]; Platelet response (pretreatment, \<100\*10\^9/L); Neutrophil response (pretreatment, \<1\*10\^9/L); Progression or relapse after HI) according to modified International Working Group (IWG) criteria.

    Time frame: Approximately 3 years

08

Study locations

18 sites
  • Florida Specialist and Cancer Institute
    Sarasota, Florida 34232, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • University of Texas, MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • St. Paul's Hospital
    Vancouver, British Columbia V6E 1M7, Canada
  • Princess Margaret Cancer Centre University Health Network
    Toronto, Ontario M5G1Z5, Canada
  • Universitaetsklinikum Duesseldorf
    Düsseldorf, 40225, Germany
  • Goethe Universität Frankfurt
    Frankfurt am Main, 60590, Germany
  • Universitaetsklinikum Leipzig
    Leipzig, 04103, Germany
  • Carmel Medical Center
    Haifa, 34362, Israel
  • Hadassah Medical Center
    Jerusalem, 9112001, Israel
  • Tel Aviv Sourasky MC
    Tel Aviv, 6423906, Israel
  • Hosp. Univ. Germans Trias I Pujol
    Badalona, 08916, Spain
  • Hosp Univ Vall D Hebron
    Barcelona, 08035, Spain
  • Hosp Univ Fund Jimenez Diaz
    Madrid, 28040, Spain
  • Clinica Univ. de Navarra
    Pamplona, 31008, Spain
  • Hosp Clinico Univ de Salamanca
    Salamanca, 37007, Spain
  • Hosp. Virgen Del Rocio
    Seville, 41013, Spain
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Sep 2025, 86 months.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's 86 months is above that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2018
First posted
Jun 29, 2018
StartActual
Jul 13, 2018
Primary completionActual
Sep 25, 2025
CompletionActual
Sep 25, 2025
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03573310
Responsible party
Sponsor
First posted
Jun 29, 2018
Start date
Jul 13, 2018
Primary completion
Sep 25, 2025
Completion
Sep 25, 2025
Last update
Dec 18, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion